BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25095527)

  • 1. Pre-transplant angiotensin II type 1 receptor antibodies: A risk factor for decreased kidney graft function in the early post-transplant period?
    Hernández-Méndez EA; Arreola-Guerra JM; Morales-Buenrostro LE; Ramírez JB; Calleja S; Castelán N; Salcedo I; Vilatobá M; Contreras AG; Gabilondo B; Granados J; Alberú J
    Clin Transpl; 2013; ():343-50. PubMed ID: 25095527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-transplant angiotensin II type 1receptor antibodies: a risk factor for decreased kidney graft function in the early post-transplant period?
    Hernández-Méndez EA; Arreola-Guerra JM; Morales-Buenrostro LE; Ramírez JB; Calleja S; Castelán N; Salcedo I; Vilatobá M; Contreras AG; Gabilondo B; Granados J; Alberú J
    Rev Invest Clin; 2014; 66(3):218-24. PubMed ID: 25695237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-nephrectomy angiotensin II type 1 receptor antibodies in living kidney donors: A concern?
    Hernández-Méndez EA; Arreola-Guerra JM; Morales-Buenrostro LE; Ramírez JB; Calleja S; Castelán N; Salcedo I; Vilatobá M; Contreras AG; Gabilondo B; Granados J; Alberú J
    Clin Transpl; 2013; ():351-5. PubMed ID: 25095528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of pre- and post-transplant HLA antibodies, donor-specific, and nondonor-specific HLA antibodies detected by ELISA in renal transplantation.
    Lee PC; Chen YL; Wang WM; Tu WC; Chen HY
    Clin Transpl; 2013; ():385-91. PubMed ID: 25095533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
    Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of therapeutic plasma exchange on angiotensin II type-1 receptor antibodies on two kidney transplant recipients.
    Yamada C; Huang Y; Norman S; Naik A; Moussa O; Samaniego M; Cooling L
    J Clin Apher; 2018 Dec; 33(6):673-677. PubMed ID: 30321467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
    Fichtner A; Süsal C; Schröder C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Dragun D; Tönshoff B
    Nephrol Dial Transplant; 2018 Jun; 33(6):1065-1072. PubMed ID: 29444269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
    Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
    Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early post-transplant immune monitoring can predict long-term kidney graft survival: soluble CD30 levels, anti-HLA antibodies and IgA-anti-Fab autoantibodies.
    Amirzargar MA; Amirzargar A; Basiri A; Hajilooi M; Roshanaei G; Rajabi G; Mohammadiazar S; Solgi G
    Hum Immunol; 2014 Jan; 75(1):47-58. PubMed ID: 24055694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss.
    Fidler S; Swaminathan R; Lim W; Ferrari P; Witt C; Christiansen FT; D'Orsogna LJ; Irish AB
    Transpl Immunol; 2013 Dec; 29(1-4):22-7. PubMed ID: 24090807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of human leukocyte antigen, donor-specific antibodies, and their impact in renal transplantation.
    Thiyagarajan UM; Bagul A; Frost J; Horsburgh T; Nicholson ML
    Transplant Proc; 2012 Jun; 44(5):1231-5. PubMed ID: 22663991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-transplant low level HLA antibody shows a composite poor outcome in long-term outcome of renal transplant recipients.
    Tian J; Li D; Alberghini TV; Rewinski M; Guo N; Bow LM
    Ren Fail; 2015 Mar; 37(2):198-202. PubMed ID: 25565259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HLA antibodies and kidney allograft outcomes in recipients with donor bone marrow cell infusion.
    Solgi G; Pourmand G; Mehrsai A; Taherimahmoudi M; Nicknam MH; Ebrahimi Rad MR; Seraji A; Asadpoor A; Ansaripor B; Nikbin B; Amirzargar A
    Iran J Immunol; 2010 Mar; 7(1):18-29. PubMed ID: 20371916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor specific antibodies before and after kidney transplant: the University of Colorado Experience.
    Cooper JE; Gralla J; Adebiyi O; Wiseman AC; Chan L
    Clin Transpl; 2013; ():407-12. PubMed ID: 25095536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.
    Loupy A; Vernerey D; Tinel C; Aubert O; Duong van Huyen JP; Rabant M; Verine J; Nochy D; Empana JP; Martinez F; Glotz D; Jouven X; Legendre C; Lefaucheur C
    J Am Soc Nephrol; 2015 Jul; 26(7):1721-31. PubMed ID: 25556173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-Transplant Angiotensin II Type 1 Receptor Antibodies and Anti-Endothelial Cell Antibodies Predict Graft Function and Allograft Rejection in a Low-Risk Kidney Transplantation Setting.
    Yu S; Huh HJ; Lee KW; Park JB; Kim SJ; Huh W; Jang HR; Kwon GY; Moon HH; Kang ES
    Ann Lab Med; 2020 Sep; 40(5):398-408. PubMed ID: 32311853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection.
    Kamali K; Abbasi MA; Farokhi B; Abbasi A; Fallah P; Seifee MH; Ghadimi N; Rezaie AR
    Exp Clin Transplant; 2009 Dec; 7(4):237-40. PubMed ID: 20353374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.